Opdivo
BMS’ Opdivo gets NHS use as adjuvant bladder cancer therapy
Phil Taylor
access, Bristol-Myers Squibb, HEOR, NHS, NICE, Opdivo, UK, urothelial carcinoma
0 Comment
News/ News/ News/ Oncology/ R&D
Novartis eyes earlier use of PD-1 drug in oesophageal cancer
Phil Taylor
BeiGene, Bristol-Myers Squibb, immuno-oncology, Keytruda, Merck & Co, Novartis, oesophageal cancer, Oncology, Opdivo, tislelizumab
0 Comment
News/ News/ News/ Oncology/ R&D
AZ takes aim at BMS’ lead in neoadjuvant NSCLC
Phil Taylor
AstraZeneca, Bristol-Myers Squibb, Imfinzi, immuno-oncology, Keytruda, Merck & Co, Non-small cell lung cancer, Oncology, Opdivo
0 Comment
BMS’ Opdivo gets late-stage oesophageal cancer nod from FDA
Phil Taylor
Bristol-Myers Squibb, immuno-oncology, Keytruda, Merck & Co, oesophageal cancer, Oncology, Opdivo, regulatory approval
0 Comment
BMS doubles down on BridgeBio alliance on SHP2 drugs
Phil Taylor
BridgeBio Pharma, Bristol-Myers Squibb, immuno-oncology, Oncology, Opdivo, partnering, SHP2
0 Comment
BMS gets FDA OK for first LAG-3 checkpoint inhibitor
Phil Taylor
Bristol-Myers Squibb, favezelimab, LAG-3, Merck & Co, Opdivo, Opdualag, regulatory approval, relatlimab
0 Comment
BMS carves out a neoadjuvant niche for Opdivo in NSCLC
Phil Taylor
Bristol-Myers Squibb, Keytruda, Merck & Co, Non-small cell lung cancer, Opdivo, Roche, Tecentriq
0 Comment